Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
Healthcare
$0.86 -4.70%
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
52W Low $0.84High $5.40
Volume 0.00M
Average 0.00M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$5.42M
FY 2025 · Annual
Net Income
-$5.21M
FY 2025 · Annual
Income Statement
CAD
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 173K | 12K | 13K | 14K | 10K |
| Gross Profit | (173K) | (12K) | (13K) | (14K) | (10K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 5.88M | 4.54M | 5.28M | 6.1M | 3.58M |
| Selling, General & Admin | 3.25M | 595K | 299K | 3.26M | 1.84M |
| Operating Expenses | 9.13M | 6.04M | 6.33M | 9.36M | 5.42M |
| Depreciation & Amortization | 173K | 12K | 13K | 14K | 10K |
| EBITDA | (9.46M) | (6.03M) | (6.31M) | (9.38M) | (5.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.61M) | (6.54M) | (6.28M) | (9.37M) | (5.43M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15 | 4K | 47K | 31K | 17K |
| Interest Expense | 15K | 18K | 14K | 7K | 10K |
| Other Income / Expenses | (443K) | (523K) | 36K | (25K) | 192K |
| Income Before Tax | (9.57M) | (6.56M) | (6.29M) | (9.4M) | (5.23M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.66M) | (484K) | 14K | (132K) | (28K) |
| Net Income | (7.91M) | (6.08M) | (6.29M) | (9.26M) | (5.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.29) | (0.20) | (0.16) | (0.21) | (0.09) |
| EPS (Diluted) | (0.29) | (0.20) | (0.16) | (0.21) | (0.09) |
| 27.58M | 29.9M | 38.65M | 44.49M | 55.74M | |
| 27.58M | 29.9M | 38.65M | 44.49M | 55.74M |
HBP.TO Earnings Waterfall · TTM
TSX:HBP.TO · Revenue to Net Income
Key Ratios
EPS$-0.04
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-42.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$3.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.04, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
No filings found.
How much revenue does HBP.TO generate?
Helix BioPharma Corp. (HBP.TO) reported $0.00 of revenue in fiscal 2025.
Is HBP.TO profitable?
Helix BioPharma Corp. (HBP.TO) reported -$5.21M of net income.
Continue the stock analysis
Jump to another research area for this company.